HCW BIOLOGICS INC. - COMMON STOCK

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

18 Nov 2024 21:27:48 By Nasdaq GlobeNewswire

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

18 Nov 2024 07:01:10 By Nasdaq GlobeNewswire

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

14 Nov 2024 16:40:41 By Nasdaq GlobeNewswire

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

23 Aug 2024 16:30:36 By Nasdaq GlobeNewswire

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

14 Aug 2024 16:35:03 By Nasdaq GlobeNewswire

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

15 May 2024 16:39:10 By Nasdaq GlobeNewswire

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

01 Apr 2024 16:10:32 By Nasdaq GlobeNewswire

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

14 Nov 2023 07:00:54 By Nasdaq GlobeNewswire

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

08 Nov 2023 07:30:19 By Nasdaq GlobeNewswire

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

01 Nov 2023 07:30:41 By Nasdaq GlobeNewswire

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

06 Sep 2023 07:30:14 By Nasdaq GlobeNewswire

HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

11 Aug 2023 07:00:22 By Nasdaq GlobeNewswire

HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders

14 Jun 2023 07:30:22 By Nasdaq GlobeNewswire

HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights

09 May 2023 07:15:14 By Nasdaq GlobeNewswire

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

27 Apr 2023 07:40:00 By Nasdaq GlobeNewswire

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

13 Apr 2023 07:15:09 By Nasdaq GlobeNewswire

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

03 Apr 2023 08:13:00 By Nasdaq GlobeNewswire

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

28 Mar 2023 16:25:00 By Nasdaq GlobeNewswire

HCW Biologics Enters CRADA with National Cancer Institute

08 Dec 2022 07:56:03 By Nasdaq GlobeNewswire

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

07 Dec 2022 07:30:00 By Nasdaq GlobeNewswire